Stayble Therapeutics AB Company Description

Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration.

The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.

Stayble Therapeutics AB (publ)

Country	Sweden
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Andreas Gerward

Contact Details

Address: Lennart Torstenssonsgatan 6 Gothenburg, 412 56 Sweden
Website	staybletherapeutics.se

Stock Details

Ticker Symbol	STABL
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0013513652
SIC Code	2834

Key Executives

Name	Position
Andreas Gerward	Chief Executive Officer
Erik Kullgren	Chief Financial Officer